Actavis Acquires U.S. Generics, Delivery Technology Firm Abrika
This article was originally published in The Pink Sheet Daily
Executive Summary
Company believes the acquisition will allow for creation of a controlled-release products “center of excellence.”
You may also be interested in...
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.
Actavis Buys Three Drugs From Roche
Acquisition gives the Icelandic generics company access to new markets, firm tells “The Pink Sheet” DAILY.